Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

Guardant Health Inc

Healthcare US GH

90.49USD
-0.71(0.78%)

Last update at 2026-03-10T20:17:00Z

Day Range

89.3992.72
LowHigh

52 Week Range

15.8141.06
LowHigh

Fundamentals

  • Previous Close 91.20
  • Market Cap3201.17M
  • Volume1373075
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-401.60499M
  • Revenue TTM603.72M
  • Revenue Per Share TTM5.17
  • Gross Profit TTM 293.21M
  • Diluted EPS TTM-4.02

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -653.44900M -384.47000M -245.90400M -69.72300M -84.22500M
Minority interest 0.00000M -20.90000M 7.50M 49.60M 41.80M
Net income -654.58800M -384.77000M -246.28300M -67.85100M -85.06300M
Selling general administrative 163.96M 206.64M 192.77M 61.40M 36.19M
Selling and marketing expenses 299.83M 191.88M 106.51M 78.33M 53.47M
Gross profit 293.21M 250.74M 194.19M 143.66M 47.43M
Reconciled depreciation 35.96M 22.27M 16.07M 13.61M 7.14M
Ebit -544.37800M -411.00100M -254.95000M -82.37100M -90.11000M
Ebitda -650.87200M -381.89300M -241.13800M -68.54200M -82.97400M
Depreciation and amortization -106.49400M 29.11M 13.81M 13.83M 7.14M
Non operating income net other -106.49400M 29.11M 13.81M 13.83M 9.97M
Operating income -544.37800M -411.00100M -254.95000M -82.37100M -92.94200M
Other operating expenses 993.92M 784.65M 541.68M 296.75M 183.58M
Interest expense 2.58M 2.58M 4.77M 1.18M 1.25M
Tax provision 1.14M 0.30M 0.38M -1.87200M 0.04M
Interest income 6.07M 3.93M 10.17M 13.74M 5.27M
Net interest income 3.49M 1.35M 5.41M 12.56M 4.01M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 1.14M 0.30M 0.38M -1.87200M 0.04M
Total revenue 449.54M 373.65M 286.73M 214.38M 90.64M
Total operating expenses 837.59M 661.74M 449.14M 226.03M 140.37M
Cost of revenue 156.32M 122.91M 92.53M 70.72M 43.21M
Total other income expense net -109.07100M 26.53M 9.05M 12.65M 4.70M
Discontinued operations - - - - -
Net income from continuing ops -654.58800M -384.77000M -246.28300M -67.85100M -84.26300M
Net income applicable to common shares -654.58800M -405.67000M -253.78300M -75.65100M -85.06300M
Preferred stock and other adjustments - - - 1.10M 1.10M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 1786.42M 1609.98M 2204.50M 2271.78M 962.53M
Intangible assets 8.98M 11.73M 14.21M 16.20M 15.41M
Earning assets - - - - -
Other current assets 27.74M 31.51M 53.05M 17.47M 11.39M
Total liab 1627.74M 1549.81M 1559.49M 916.19M 114.54M
Total stockholder equity 158.68M 60.18M 645.00M 1298.49M 798.39M
Deferred long term liab - - - - -
Other current liab 108.26M -21.87800M 152.93M 44.29M 37.12M
Common stock 0.00100M 0.00100M 0.00100M 0.00100M 0.00100M
Capital stock 0.00100M 0.00100M 0.00100M 0.00100M 0.00100M
Retained earnings -2141.86200M -1662.41300M -1007.82500M -606.59200M -352.80900M
Other liab - 9.18M 3.93M 1.52M 8.55M
Good will 3.29M 3.29M 3.29M 3.29M 3.29M
Other assets - 36.45M 60.94M 17.21M 4.88M
Cash 1133.54M 141.65M 492.20M 832.98M 143.23M
Cash and equivalents - - - - -
Total current liabilities 205.92M 193.22M 194.69M 66.81M 72.73M
Current deferred revenue 17.96M 17.40M 11.33M 8.55M 12.28M
Net debt 220.23M 1227.64M 868.67M 14.88M -109.97200M
Short term debt 27.95M 21.88M 12.86M 6.63M 7.14M
Short long term debt - - - - -
Short long term debt total 1353.76M 1369.28M 1360.87M 847.86M 33.26M
Other stockholder equity 2304.22M 1742.11M 1657.59M 1902.39M 1150.09M
Property plant equipment - 167.92M 313.90M 62.78M 72.81M
Total current assets 1347.11M 1191.59M 1114.13M 1888.36M 597.36M
Long term investments - 0.00000M 698.03M 246.60M 268.78M
Net tangible assets - 45.16M 627.51M 1336.15M 779.69M
Short term investments 35.10M 869.58M 440.55M 961.90M 379.57M
Net receivables 88.78M 97.26M 97.65M 53.30M 47.99M
Long term debt 1139.97M 1137.39M 1134.82M 806.29M -
Inventory 61.95M 51.60M 30.67M 22.72M 15.18M
Accounts payable 51.74M 175.82M 17.58M 7.34M 16.20M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -3.67500M -19.52200M -4.76400M 2.70M 1.11M
Additional paid in capital - - - - -
Common stock total equity - 0.00100M 0.00100M 0.00100M 0.00100M
Preferred stock total equity - - - - -
Retained earnings total equity - -1662.41300M -1007.82500M -606.59200M -352.80900M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 124.18M 61.45M 60.94M 17.21M 4.88M
Deferred long term asset charges - - - - -
Non current assets total 439.31M 418.39M 1090.37M 383.42M 365.18M
Capital lease obligations 213.80M 231.89M 226.05M 41.56M 40.40M
Long term debt total - 1137.39M 1134.82M 806.29M -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 149.82M 51.30M -563.02700M -288.95700M -132.82500M
Change to liabilities 9.87M 37.57M -3.22200M 15.34M 26.43M
Total cashflows from investing activities 149.82M -63.15500M -617.08600M -317.57000M -153.02800M
Net borrowings -0.07100M -0.78400M 1042.70M -0.12800M -0.44300M
Total cash from financing activities -189.09300M -66.82400M 1410.31M 367.30M 293.16M
Change to operating activities 11.91M 0.43M -23.08100M 6.86M 5.55M
Net income -654.58800M -384.77000M -246.28300M -67.85100M -84.26300M
Change in cash -842.62800M -340.68900M 689.75M 2.68M 67.95M
Begin period cash flow 492.29M 832.98M 143.23M 140.54M 72.60M
End period cash flow -350.34000M 492.29M 832.98M 143.23M 140.54M
Total cash from operating activities -309.46300M -209.01700M -103.92700M -47.13400M -72.18500M
Issuance of capital stock - 0.00000M 355.73M 350.43M 254.01M
Depreciation 35.96M 22.27M 16.07M 13.61M 7.14M
Other cashflows from investing activities -23.96600M -39.42200M -17.88600M -9.89600M -132.82500M
Dividends paid - - 7.09M - 3.16M
Change to inventory -20.92600M -7.95700M -7.53500M -6.04500M -1.84900M
Change to account receivables 0.38M -44.35300M -5.46300M -7.38900M -22.90300M
Sale purchase of stock 9.32M 9.75M 7.09M -0.72300M -0.17200M
Other cashflows from financing activities -200.96300M -76.43100M 1054.75M 17.31M 42.93M
Change to netincome 104.27M 153.88M 151.14M 17.25M 6.84M
Capital expenditures 77.46M 75.03M 54.06M 21.29M 20.20M
Change receivables 0.38M -44.35300M -5.46300M -7.38900M -22.90300M
Cash flows other operating 208.41M -1.06900M -17.37800M -7.54400M -3.16400M
Exchange rate changes - - - - -
Cash and cash equivalents changes -348.74000M -338.99600M 689.29M 2.60M 67.95M
Change in working capital 61.56M -40.46800M -47.66500M -6.09200M -1.12700M
Stock based compensation 94.69M 151.45M 144.11M 16.95M 6.85M
Other non cash items 152.91M 29.61M 18.68M -2.15700M -0.01300M
Free cash flow -386.92400M -284.05200M -157.98600M -68.41900M -92.38800M

Peer Comparison

Sector: Healthcare Industry: Diagnostics & Research

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
GH
Guardant Health Inc		 -0.71 0.78% 90.49 - - 3.94 14.01 4.27 -5.5564
TMO
Thermo Fisher Scientific Inc		 -9.89 1.94% 500.08 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation		 -3.58 1.80% 195.22 29.09 28.01 5.67 3.20 6.00 19.09
A
Agilent Technologies Inc		 -1.21 1.04% 115.43 34.36 26.39 6.59 7.14 6.78 23.56
IDXX
IDEXX Laboratories Inc		 -11.6 1.90% 598.85 49.99 45.66 11.29 27.85 11.46 34.46

Reports Covered

Stock Research & News

View All

Profile

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Guardant Health Inc

3100 Hanover Street, Palo Alto, CA, United States, 94304

Key Executives

Name Title Year Born
Dr. Helmy Eltoukhy Ph.D. Co-Founder, Co-CEO & Chairman 1979
Dr. AmirAli Talasaz Ph.D. Co-CEO & Director 1980
Mr. Michael Bell Chief Financial Officer 1969
Mr. John G. Saia Chief Legal Officer 1973
Dr. Craig Eagle M.D. Chief Medical Officer 1967
Mr. Christopher Freeman Chief Commercial Officer of Oncology Bus. 1974
Mr. Andy Ament Sr. VP of Operations NA
Darya Chudova Sr. VP of Technology NA
Mr. Kumud Kalia Chief Information Officer NA
Ms. Jennifer Higgins VP of Public Affairs NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.